Advisory Board
Azaya significantly leverages the consulting services of four highly regarded experts in the pharmaceutical industry.
Steve Weitman, M.D., Ph.D.
Dr. Weitman is trained as a pharmacologist, toxicologist and a pediatric oncologist and for the last 4+ years served as senior vice president and chief medical officer at ILEX Oncology, Inc. in San Antonio. He presented a new ILEX leukemia drug to the FDA ODAC panel in December, 2004 and both the panel and the FDA voted to approve the drug. Steve has extensive experience in preclinical and early clinical studies.
Max Talbott, Ph.D.
Dr. Talbott is a senior regulatory consultant and also serves as Senior Vice President, Worldwide Commercial Development for Introgen Therapeutics, Inc. in Austin, Texas. He has Senior VP Regulatory experience at DuPont Pharmaceuticals Company, Bristol-Myers-Squibb Pharma Company, Aventis Pharmaceuticals and its predecessor Rhone-Poulenc-Rorer. His broad background includes experience in the FDA approval of over 25 new drugs including Taxotere (docetaxel), which the Company’s lead product in its PSL reformulation.
Ian Clements
Mr. Clements is the former Vice President, Corporate Development and Commercial Operations for ILEX Oncology, Inc. He has over 16 years experience in the pharmaceutical industry including business development and licensing, product and portfolio management, new product launch, and marketing and selling. Mr. Clements led the team at Pharmacia & Upjohn that launched CAMPTOSAR for colorectal cancer.
Pat Shannon. Ph.D.
Dr. Shannon is a consultant specializing in the development of new drugs and biologics in oncology including pharmaceutical program/project management, preclinical development, CMC (chemistry, manufacturing, controls), and IND and NDA preparations. He has over 25 years experience in the pharmaceutical industry. Previous experience include senior Project Management positions at OSI Pharmaceuticals where he was project leader of the Tarceva NDA (NSCLC, pancreatic cancer) and as a senior manager in pharmaceutical development at ILEX oncology where he was head of departments covering CMC (manufacturing, QC, methods development and validation, process chemistry development, formulation and finishing), Pharmacology, Toxicology, Drug Product, and Clinical Trial Material management.
